 Connection
Thomas Flaig to Cystectomy
This is a "connection" page, showing publications Thomas Flaig has written about Cystectomy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.247 |
|
|
|
-
Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu T, Chatzkel J, Koie T, Hoimes CJ, Puente J, Zakharia Y, Rosenbaum E, Boehm K, Loriot Y, Bedke J, Powles TB, Necchi A, Wiechno P, Álvarez-Fernández C, Kim TH, Oliveira N, Flaig TW, Wirtz HS, Mihm M, Huang Q, Rogiers A, Homet Moreno B, Gómez de Liaño A. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. N Engl J Med. 2026 Jul 23; 395(4):338-348.
Score: 0.239
-
Plimack ER, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, Ross EA, Grundy E, Choi W, Dinney CPN, Lee IC, Fong M, Scott Lucia M, Daneshmand S, Theodorescu D, Goldkorn A, Lerner SP, Flaig TW, McConkey DJ. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Eur Urol. 2024 Oct; 86(4):297-300.
Score: 0.207
-
Eule CJ, Warren A, Molina Kuna E, Callihan EB, Kim SP, Flaig TW. Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen. Urology. 2024 06; 188:118-124.
Score: 0.204
-
Flaig TW, Tangen CM, Daneshmand S, Alva AS, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM, Lerner SP. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Eur Urol. 2023 09; 84(3):341-347.
Score: 0.193
-
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 09; 16(9):1041-1053.
Score: 0.138
-
Flaig TW. The Changing Treatment Landscape for Metastatic Urothelial Carcinoma. J Natl Compr Canc Netw. 2018 05; 16(5S):636-638.
Score: 0.135
-
Gupta S, Hensley PJ, Li R, Choudhury A, Daneshmand S, Faltas BM, Flaig TW, Grass GD, Grivas P, Hansel DE, Hassanzadeh C, Kassouf W, Kukreja J, Mendoza-Valdés A, Moschini M, Mouw KW, Navai N, Necchi A, Rosenberg JE, Ross JS, Siefker-Radtke AO, Taylor J, Willliams SB, Zlotta AR, Buckley R, Kamat AM. Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Eur Urol. 2026 Jan; 89(1):18-28.
Score: 0.055
-
Lerner SP, McConkey DJ, Tangen CM, Meeks JJ, Flaig TW, Hua X, Daneshmand S, Alva AS, Lucia MS, Theodorescu D, Goldkorn A, Milowsky MI, Choi W, Bangs R, Gustafson DL, Plets M, Thompson IM. Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Clin Cancer Res. 2024 01 17; 30(2):444-449.
Score: 0.050
-
Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol. 2014 Aug; 32(6):826-32.
Score: 0.026
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|